Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Pancreatic Cancer Basic Research Services

Pancreatic Cancer Basic Research Services

Pancreatic cancer (PC) is a cancer that begins in the pancreas. Pancreatic adenocarcinoma is the most common type of pancreatic cancer and an aggressive malignancy characterized by a high rate of distant metastasis and recurrence. Alfa Cytology is a leading custom service provider with experience in pancreatic cancer basic research.

Significance of Pancreatic Cancer Basic Research

Compared with other types of cancer, pancreatic cancer has a unique tumor microenvironment (TEM) that accounts for more than 80% of total pancreatic tumor masses, consisting of the extracellular matrix and numerous types of cellular components. Among them, cancer-associated fibroblasts (CAFs) produce an extracellular matrix and regulate tumor behavior, forming a barrier for drug delivery and leading to medication resistance. Therefore, basic research on pancreatic cancer is urgent.

The pancreatic cancer microenvironment is quite complex.Fig. 1 PDAC desmoplasia. (Orth, M.; et al., 2019)

Our Services

Alfa Cytology proudly offers a full range of basic pancreatic cancer research services. Based on robust platforms, powerful analytics, cross-platform collaborations, and years of experience in pancreatic cancer research, we are committed to providing our customers with optimal customized services to meet basic pancreatic cancer research needs.

Pathology Research on Pancreatic Cancer

Pathological staging is critical in determining the most appropriate therapy and prognostic group. We performed histopathological studies of pancreatic cancer according to the following criteria.

  • Presence of mucins
  • Nuclear polymorphism
  • Number of mitoses
  • Comparison of the tubular structure and solid growth.

Pancreatic Cancer Cell Research

Alfa Cytology focus on pancreatic cancer cells and is committed to providing our clients with optimal and personalized services to support pancreatic cancer preclinical research projects, including but not limited to the following.

Pancreatic Cancer Stem Cell (CSC) Research

CSCs are rare quiescent cells that can self-renew and play an important role in tumor recurrence, metastasis, and drug resistance. Therefore, Alfa Cytology identifies CSC as a potential target for pancreatic cancer therapy.

Pancreatic Cancer Fibroblast (CAF) Research

As a major non-neoplastic component of the pancreatic tumor microenvironment, CAFs are potential targets for the treatment of pancreatic cancer. Alfa Cytology provides a series of research services for CAFs.

  • Extracellular matrix protein secretion
  • Interstitial formation test
  • Cytokines influence regulation
  • Immunosuppression test
  • Chemotherapy resistance test

Pancreatic Cancer Genetic/Molecular Research

Alfa Cytology provides suitable solutions for pancreatic cancer gene/molecular exploration according to the specific needs of customers.

  • Next-generation sequencing (NGS) technology
  • Gene enrichment technique
  • Mutation pathway detection
  • Genetic diversity study

Pancreatic Cancer-related Microbiota Research

Compared with normal pancreas samples, pancreatic cancer tissue had a unique intracavitary bacterial profile with a higher bacterial abundance. Alfa Cytology provides pancreatic cancer-related microbial testing services.

  • Microbial diversity survey
  • Microbiome interactions
  • Microbial marker

Why Choose Us?

Advantages Customized Solutions Scientific Excellence Collaborative Approach Data
Security
Worldwide Service

Alfa Cytology has extensive expertise in pancreatic cancer basic research, an excellent project management team, and the best after-sales service. If you have any questions about our pancreatic cancer Basic research services, please feel free to contact us.

Reference

  1. Orth, M., et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14, 141 (2019). https://doi.org/10.1186/s13014-019-1345-6
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.